uniQure (QURE) announced the appointment of Kylie O’Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O’Keefe will lead the development and execution of uniQure’s global commercialization strategy for AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. Her responsibilities include all commercial functions and medical affairs. Ms. O’Keefe was most recently Chief Commercial Officer at PTC Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
- Positive Outlook for uniQure’s AMT-130 Program Drives Buy Rating Amid Regulatory Advancements and Robust Clinical Framework
- Buy Rating for uniQure Driven by Promising AMT-130 Advancements and Strategic FDA Alignment
- RBC Capital views FDA flexibility on another HD drug as positive for PTC’s ‘518
- uniQure’s AMT-130 Gains Momentum with FDA Support and Promising Clinical Outlook